Polar Capital Holdings Plc Sells 1,155,046 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Polar Capital Holdings Plc trimmed its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 42.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,565,831 shares of the biopharmaceutical company's stock after selling 1,155,046 shares during the quarter. Polar Capital Holdings Plc owned approximately 2.36% of Celldex Therapeutics worth $39,569,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. EverSource Wealth Advisors LLC lifted its holdings in Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 878 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Celldex Therapeutics in the 4th quarter worth approximately $81,000. KBC Group NV lifted its holdings in Celldex Therapeutics by 79.1% in the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 1,647 shares during the last quarter. AlphaQuest LLC lifted its holdings in Celldex Therapeutics by 171.0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after purchasing an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in Celldex Therapeutics in the 4th quarter worth approximately $121,000.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on CLDX. Morgan Stanley reduced their target price on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Friday, May 9th. Cantor Fitzgerald restated an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. UBS Group decreased their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Canaccord Genuity Group started coverage on Celldex Therapeutics in a report on Monday, April 28th. They set a "buy" rating and a $64.00 price target for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Tuesday, May 6th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $53.90.

Celldex Therapeutics Price Performance

Shares of CLDX traded down $0.47 during mid-day trading on Tuesday, reaching $20.44. The company had a trading volume of 248,272 shares, compared to its average volume of 889,624. Celldex Therapeutics, Inc. has a twelve month low of $14.40 and a twelve month high of $47.00. The company's 50-day moving average is $18.90 and its 200-day moving average is $22.52. The company has a market capitalization of $1.36 billion, a P/E ratio of -7.97 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The company had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.08 million. As a group, equities analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.